Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Campbell McInnes

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Biochemical Pharmacology|January 27, 2009
Non-ATP competitive protein kinase inhibitors as anti-tumor therapeuticsLindsay O Kirkland, Campbell McInnes
Chemistry & Biology|July 29, 2006
Catch the kinase conformerCampbell McInnes, Mokdad Mezna, George Kontopidis
Journal of Visualized Experiments : Jove|November 12, 2015
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK InhibitorsPadmavathy Nandha Premnath, Sandra Craig, Campbell McInnes
Current Topics in Medicinal Chemistry|April 28, 2005
Progress in the discovery of polo-like kinase inhibitorsCampbell McInnes, Mokdad Mezna, Peter M Fischer
Plos One|October 8, 2013
Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor α and β subtypes: a molecular modeling studyPan Wang, Campbell McInnes, Bao Ting Zhu
Journal of Medicinal Chemistry|January 6, 2006
Protein structures in virtual screening: a case study with CDK2Mark P Thomas, Campbell McInnes, Peter M Fischer
Expert Opinion on Drug Discovery|May 14, 2014
Current assessment of polo-like kinases as anti-tumor drug targetsSandra N Craig, Michael D Wyatt, Campbell McInnes
Expert Opinion on Drug Discovery|December 16, 2022
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancerJessy M Stafford, Michael D Wyatt, Campbell McInnes
Cancer Gene Therapy|May 16, 2025
Structural regulation of PLK1 activity: implications for cell cycle function and drug discoveryDanda Chapagai, Klaus Strebhardt, Michael D Wyatt, et al.
ACS Chemical Biology|July 11, 2023
Structural Basis for Variations in Polo-like Kinase 1 Conformation and Intracellular Stability Induced by ATP-Competitive and Novel Noncompetitive Abbapolin InhibitorsDanda Chapagai, George Merhej, Campbell McInnes, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Biochemical Pharmacology|January 27, 2009
Non-ATP competitive protein kinase inhibitors as anti-tumor therapeuticsLindsay O Kirkland, Campbell McInnes
Chemistry & Biology|July 29, 2006
Catch the kinase conformerCampbell McInnes, Mokdad Mezna, George Kontopidis
Journal of Visualized Experiments : Jove|November 12, 2015
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK InhibitorsPadmavathy Nandha Premnath, Sandra Craig, Campbell McInnes
Current Topics in Medicinal Chemistry|April 28, 2005
Progress in the discovery of polo-like kinase inhibitorsCampbell McInnes, Mokdad Mezna, Peter M Fischer
Plos One|October 8, 2013
Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor α and β subtypes: a molecular modeling studyPan Wang, Campbell McInnes, Bao Ting Zhu
Journal of Medicinal Chemistry|January 6, 2006
Protein structures in virtual screening: a case study with CDK2Mark P Thomas, Campbell McInnes, Peter M Fischer
Expert Opinion on Drug Discovery|May 14, 2014
Current assessment of polo-like kinases as anti-tumor drug targetsSandra N Craig, Michael D Wyatt, Campbell McInnes
Expert Opinion on Drug Discovery|December 16, 2022
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancerJessy M Stafford, Michael D Wyatt, Campbell McInnes
Cancer Gene Therapy|May 16, 2025
Structural regulation of PLK1 activity: implications for cell cycle function and drug discoveryDanda Chapagai, Klaus Strebhardt, Michael D Wyatt, et al.
ACS Chemical Biology|July 11, 2023
Structural Basis for Variations in Polo-like Kinase 1 Conformation and Intracellular Stability Induced by ATP-Competitive and Novel Noncompetitive Abbapolin InhibitorsDanda Chapagai, George Merhej, Campbell McInnes, et al.
Pageof 7